Identifying therapeutic target genes for stroke through systematic druggable Mendelian randomization analysis

Area of Science:

• Genetics and Genomics
• Pharmacology
• Neuroscience

Background:

• Stroke is a leading cause of death and disability worldwide.
• Identifying novel therapeutic targets is crucial for effective stroke management.
• Existing treatments for stroke have limitations, necessitating research into new strategies.

Purpose of the Study:

• To systematically identify druggable genes causally associated with stroke risk.
• To integrate genetic and transcriptomic data for comprehensive analysis.
• To discover potential therapeutic targets and drug candidates for stroke.

Main Methods:

• Compiled a database of 5883 druggable genes.
• Integrated stroke genome-wide association study (GWAS) data with expression quantitative trait loci (eQTLs) from blood and brain tissues.
• Performed two-sample Mendelian randomization and colocalization analyses.
• Utilized protein-protein interaction networks and drug databases for further analysis.

Main Results:

• Identified ten gene-stroke associations, with five validated through colocalization analysis.
• Highlighted five core druggable genes: protein tyrosine kinase 2, cyclin-dependent kinase 6, ring finger protein 43, papilin proteoglycan-like sulfated glycoprotein, and coagulation factor II.
• Identified myosin light chain kinase inhibitor 7, staurosporine, simvastatin, and cortisol succinate as potential therapeutic compounds.

Conclusions:

• The study successfully identified potential stroke mechanisms and therapeutic targets using integrated multi-omics data.
• Five key druggable genes were pinpointed as potential targets for stroke intervention.
• Identified drug candidates offer a foundation for future clinical applications and drug development strategies in stroke treatment.